Scancell Ltd. Researcher Describes New Findings in Lung Cancer (SC134-TCB targeting fucosyl-GM1, a T cell engaging antibody with potent anti-tumour activity in preclinical small-cell lung cancer models).

A recent study conducted by researchers at Scancell Ltd. in Nottingham, United Kingdom, has identified a potential treatment option for small-cell lung cancer (SCLC). The researchers developed a bispecific antibody called SC134-TCB, which targets a glycolipid called Fucosyl-GM1 (FucGM1) that is overexpressed in SCLC tumors. In preclinical models, SC134-TCB demonstrated potent anti-tumor activity, effectively activating T cells and resulting in tumor-free survival in a human PBMC admixed setting. Combination treatment with Atezolizumab further enhanced survival and tumor growth inhibition. These findings suggest that SC134-TCB could be a promising immunotherapy treatment option for SCLC patients. [Extracted from the article]